1. Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain

   • Sara Emad El-Agamy
   • Amal Kamal Abdel-Aziz
   • Samar S. Azab

   Review Article 06 April 2019 Pages: 1 - 14

   

2. Uveal melanoma: physiopathology and new in situ-specific therapies

   • E. B. Souto
   • A. Zielinska
   • A. M. Silva

   Review Article 11 May 2019 Pages: 15 - 32

   

3. Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer

   • Mayumi Kobayashi-Kato
   • Mayu Yunokawa
   • Kenji Tamura

   Original Article 13 April 2019 Pages: 33 - 39

   

4. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial

   • Arnauld C. Verschuur
   • Viera Bajčiová
   • Katherine A. Janeway

   Original Article Open access 20 April 2019 Pages: 41 - 50

5. Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics

   • Hitesh B. Mistry
   • Gabriel Helmlinger
   • James Yates

   Original Article Open access 24 April 2019 Pages: 51 - 60

   

6. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer

   • Zhuanglin Li
   • Mingxue Wang
   • Xuejing Yao

   Original Article 29 April 2019 Pages: 61 - 72

   

7. Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial

   • Jianhua Chen
   • Bingyang Liu
   • Peng Zhang

   Original Article 30 April 2019 Pages: 73 - 81

   

8. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin^®) in patients with HER2-positive metastatic breast cancer

   • Xiaoying Chen
   • Cheryl Li
   • Donghua Yin

   Original Article Open access 03 May 2019 Pages: 83 - 92

   

9. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [¹⁴C]-labeled idasanutlin and an intravenous tracer dose of [¹³C]-labeled idasanutlin in a single cohort of patients with solid tumors

   • Zsuzsanna Pápai
   • Lin-Chi Chen
   • Jianguo Zhi

   Original Article 06 May 2019 Pages: 93 - 103

   

10. Orally administered salecan ameliorates methotrexate-induced intestinal mucositis in mice

    • Yan Gao
    • Qi Sun
    • Jianfa Zhang

    Original Article 08 May 2019 Pages: 105 - 116

    

11. Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice

    • Bárbara A. A. Porto
    • Cinthia F. Monteiro
    • Flaviano S. Martins

    Original Article 11 May 2019 Pages: 117 - 126

    

12. Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period

    • Zhan Shi
    • Xi Tang
    • Jie Zhuang

    Original Article 13 May 2019 Pages: 127 - 137

    

13. Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer

    • Malmaruha Arasaratnam
    • Megan Crumbaker
    • Howard Gurney

    Original Article 13 May 2019 Pages: 139 - 146

    

14. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting

    • Kazuki Tanaka
    • Naoki Inui
    • Takafumi Suda

    Original Article 13 May 2019 Pages: 147 - 153

15. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study

    • Xiang-Yun Kong
    • Jian-Xun Lu
    • Wei Jiang

    Original Article 13 May 2019 Pages: 155 - 161

    

16. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

    • Tara L. Lin
    • Laura F. Newell
    • Arthur C. Louie

    Original Article Open access 16 May 2019 Pages: 163 - 173

    

17. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

    • Dan Lu
    • Chunze Li
    • Sandhya Girish

    Original Article 17 May 2019 Pages: 175 - 185

    

18. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer

    • Bo Li
    • Dalon Xie
    • Hui Zhang

    Original Article 21 May 2019 Pages: 187 - 194

    

19. Renin–angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis

    • Toshinori Hirai
    • Yukari Shuji
    • Toshimasa Itoh

    Original Article 23 May 2019 Pages: 195 - 202

    

20. Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer

    • Swan Lin
    • Dana J. Nickens
    • Weiwei Tan

    Original Article 24 May 2019 Pages: 203 - 211

    

21. Qualitative and quantitative variations in liver function thresholds among clinical trials in cancer: a need for harmonization

    • Edwin Wang
    • Fei Song
    • Paul Mathew

    Short Communication 22 April 2019 Pages: 213 - 216

    

22. Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity

    • Daniel F. Pease
    • Bruce A. Peterson
    • Keith M. Skubitz

    Short Communication 30 April 2019 Pages: 217 - 221

    

23. Efficacy of immunotherapy, gut microbiota and impact of antibiotic use: are there confounding factors?

    • G. Milano

    Letter to the Editor 12 April 2019 Pages: 223 - 224

24. Stress resilience and survival among cancer patients: is there any absolute truth?

    • Raffaella Mormile

    Letter to the Editor 30 April 2019 Pages: 225 - 226